Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Intravenous Ferric Carboxymaltose As Sole Anemia Therapy In Patients With Lymphoid Malignancies, Chemotherapy-Induced Anemia and Functional Iron Deficiency

Michael Hedenus, MD, PhD, Torbjorn Karlsson, MD, PhD, Heinz Ludwig, MD, Marcel Felder, MD, Bernard Roubert, MSc, Gunnar Birgegard, MD, PhD

Blood (2013) 122 (21): 3439.

https://doi.org/10.1182/blood.V122.21.3439.3439

Published: 2013

Journal Articles

Hematologic Responses in Patients with Aplastic Anemia Treated with Deferasirox: A Post-Hoc Analysis From the EPIC Study

Jong Wook Lee, MD, PhD, Sung-Soo Yoon, MD, PhD, Zhi Xiang Shen, MD, Arnold Ganser, MD, Hui-Chi Hsu, MD, Ali El-Ali, MD, Dany Habr, MD, Bernard Roubert, PhD, John B. Porter, MD, on behalf of the EPIC study investigators

Blood (2011) 118 (21): 1344.

https://doi.org/10.1182/blood.V118.21.1344.1344

Published: 2011

Journal Articles

Geographical Differences In Transfusion and Iron Chelation Practices In 1558 Patients with Transfusion-Dependent Anemias

Vip Viprakasit, MD, DPhil, Norbert Gattermann, MD, Jong Wook Lee, MD, John B. Porter, MD, Ali Taher, MD, Dany Habr, MD, Bernard Roubert, PhD, Gabor Domokos, PhD, Maria Domenica Cappellini, MD

Blood (2010) 116 (21): 4272.

https://doi.org/10.1182/blood.V116.21.4272.4272

Published: 2010

Journal Articles

Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years

Dudley Pennell, MD, John B. Porter, MD, Maria Domenica Cappellini, MD, Lee Lee Chan, MD, Amal El-Beshlawy, MD, Yesim Aydinok, MD, Hishamshah Ibrahim, MD, Chi-Kong Li, MD, Vip Viprakasit, MD, DPhil, Mohsen Saleh Elalfy, MD, Antonis Kattamis, MD, Gillian Smith, MSc, Dany Habr, MD, Gabor Domokos, PhD, Bernard Roubert, PhD, Ali Taher, MD

Blood (2010) 116 (21): 4276.

https://doi.org/10.1182/blood.V116.21.4276.4276

Published: 2010

Journal Articles

Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria

Norbert Gattermann, MD, Carlo Finelli, MD, Matteo Della Porta, MD, Pierre Fenaux, MD, PhD, Michael Stadler, MD, Agnès Guerci-Bresler, MD, Mathias Schmid, MD, Kerry Taylor, MD, Dominique Vassilieff, MD, Dany Habr, MD, Andrea Marcellari, MS, MT(ASCP), Bernard Roubert, PhD, Christian Rose, MD

Blood (2010) 116 (21): 2912.

https://doi.org/10.1182/blood.V116.21.2912.2912

Published: 2010

Journal Articles

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

Jong Wook Lee, Sung-Soo Yoon, Zhi Xiang Shen, Arnold Ganser, Hui-Chi Hsu, Dany Habr, Gabor Domokos, Bernard Roubert, John B. Porter, on behalf of the EPIC study investigators

Blood (2010) 116 (14): 2448–2454.

https://doi.org/10.1182/blood-2010-01-261289

Published: 2010

Journal Articles

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Amal El-Beshlawy, Lee Lee Chan, Yesim Aydinok, Mohsen Saleh Elalfy, Pranee Sutcharitchan, Chi-Kong Li, Hishamshah Ibrahim, Vip Viprakasit, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher

Blood (2010) 115 (12): 2364–2371.

https://doi.org/10.1182/blood-2009-04-217455

Published: 2010

Journal Articles

Improved Patient Satisfaction, Adherence and Health-Related Quality of Life with Deferasirox (Exjade®) in β-Thalassemia Patients Previously Receiving Other Iron Chelation Therapies.

John B. Porter, Miranda Athanasiou-Metaxa, Donald K. Bowden, Jacques Troncy, Dany Habr, Gabor Domokos, Bernard Roubert, Diana Rofail, Adam Gater, Jean-François Baladi, M. Domenica Cappellini

Blood (2009) 114 (22): 2486.

https://doi.org/10.1182/blood.V114.22.2486.2486

Published: 2009

Journal Articles

Deferasirox (Exjade®) ≥30 Mg/Kg/Day Is Effective in Reducing Iron Burden in Thalassemia Major Patients Previously Chelated with Monotherapy or Combination Therapy.

Ali Taher, Mohsen Saleh Elalfy, Amal El-Beshlawy, Dunhua Zhou, Lee Lee Chan, Chi-Kong Li, Kai-Hsin Lin, John B. Porter, Pranee Sutcharitcharan, Dany Habr, Gabor Domokos, Bernard Roubert, M. Domenica Cappellini

Blood (2009) 114 (22): 4058.

https://doi.org/10.1182/blood.V114.22.4058.4058

Published: 2009

Journal Articles

Efficacy and Safety of Deferasirox (Exjade®) in β-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.

Dudley J. Pennell, John B. Porter, M. Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher

Blood (2009) 114 (22): 4062.

https://doi.org/10.1182/blood.V114.22.4062.4062

Published: 2009

Journal Articles

Correlation Between Decreased Serum Ferritin and Improved Liver Transaminases During Deferasirox (Exjade®) Treatment in Iron-Overloaded Patients with Myelodysplastic Syndromes.

Norbert Gattermann, Mathias Schmid, Agnès Guerci-Bresler, Matteo Della Porta, Kerry Taylor, Dany Habr, Gabor Domokos, Bernard Roubert, Pierre Fenaux

Blood (2009) 114 (22): 3803.

https://doi.org/10.1182/blood.V114.22.3803.3803

Published: 2009

Journal Articles

Deferasirox (Exjade®) Is Effective and Well Tolerated in Chelation-Naive and Previously Chelated Patients with Transfusion-Dependent Myelodysplastic Syndromes (MDS).

Mathias Schmid, Agnès Guerci-Bresler, Matteo Della Porta, Kerry Taylor, Dany Habr, Gabor Domokos, Bernard Roubert, Christian Rose, Norbert Gattermann, MD, PhD

Blood (2009) 114 (22): 3806.

https://doi.org/10.1182/blood.V114.22.3806.3806

Published: 2009

Journal Articles

History of Hepatitis B or C Does Not Affect Safety and Efficacy of Deferasirox (Exjade®) in Thalassemia Major Patients: Sub-Analysis of the EPIC Trial.

M. Domenica Cappellini, Mohsen Saleh Elalfy, Amal El-Beshlawy, Antonis Kattamis, Lee Lee Chan, ChunFu Li, Kai-Hsin Lin, Giovanni Quarta, Pranee Sutcharitchan, Ali Taher, Dany Habr, Gabor Domokos, Bernard Roubert, John B. Porter

Blood (2009) 114 (22): 5107.

https://doi.org/10.1182/blood.V114.22.5107.5107

Published: 2009

NARROW

Intravenous Ferric Carboxymaltose As Sole Anemia Therapy In Patients With Lymphoid Malignancies, Chemotherapy-Induced Anemia and Functional Iron Deficiency

Hematologic Responses in Patients with Aplastic Anemia Treated with Deferasirox: A Post-Hoc Analysis From the EPIC Study

Geographical Differences In Transfusion and Iron Chelation Practices In 1558 Patients with Transfusion-Dependent Anemias

Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years

Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

Improved Patient Satisfaction, Adherence and Health-Related Quality of Life with Deferasirox (Exjade®) in β-Thalassemia Patients Previously Receiving Other Iron Chelation Therapies.

Deferasirox (Exjade®) ≥30 Mg/Kg/Day Is Effective in Reducing Iron Burden in Thalassemia Major Patients Previously Chelated with Monotherapy or Combination Therapy.

Efficacy and Safety of Deferasirox (Exjade®) in β-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.

Correlation Between Decreased Serum Ferritin and Improved Liver Transaminases During Deferasirox (Exjade®) Treatment in Iron-Overloaded Patients with Myelodysplastic Syndromes.

Deferasirox (Exjade®) Is Effective and Well Tolerated in Chelation-Naive and Previously Chelated Patients with Transfusion-Dependent Myelodysplastic Syndromes (MDS).

History of Hepatitis B or C Does Not Affect Safety and Efficacy of Deferasirox (Exjade®) in Thalassemia Major Patients: Sub-Analysis of the EPIC Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only